CFA
LCTX icon

Carroll Financial Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Carroll Financial Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,431
Closed -$39K – 1337
2018
Q3 		$39K Hold
19,431
– – ﹤0.01% 554
2018
Q2 		$35K Hold
19,431
– – ﹤0.01% 557
2018
Q1 		$45K Buy
+19,431
New +$45.6K ﹤0.01% 509
2017
Q4 		– Sell
-19,431
Closed -$47K – 1264
2017
Q3 		$47K Hold
19,431
– – 0.01% 502
2017
Q2 		$53K Hold
19,431
– – 0.01% 483
2017
Q1 		$58K Hold
19,431
– – 0.01% 448
2016
Q4 		$61K Hold
19,431
– – 0.01% 427
2016
Q3 		$66K Hold
19,431
– – 0.01% 419
2016
Q2 		$44K Hold
19,431
– – 0.01% 466
2016
Q1 		$48K Sell
19,431
-1,632
-8% -$3.64K 0.01% 434
2015
Q4 		$69K Hold
21,063
– – 0.01% 348
2015
Q3 		$63K Hold
21,063
– – 0.01% 352
2015
Q2 		$62K Buy
+21,063
New +$81.7K 0.01% 336

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Carroll Financial Associates's LCTX Position: Q4 2018 in Review

Carroll Financial Associates sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 19,431 shares — an estimated $39K sold.

Carroll Financial Associates first reported a position in LCTX in Q2 2015 and held it in 13 quarters. The position peaked at $69K in Q4 2015. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

  • Carroll Financial Associates reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Carroll Financial Associates sold 19,431 Lineage Cell Therapeutics shares in Q4 2018, an estimated $39K.
  • Carroll Financial Associates first reported a position in Lineage Cell Therapeutics in Q2 2015 and held it in 13 quarters.
  • Carroll Financial Associates's Lineage Cell Therapeutics position peaked at $69K in Q4 2015.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Carroll Financial Associates's 13F filing for Q4 2018, filed 11 Jan 2019.